Long-term effects of bosentan in patients with HIV-associated pulmonary arterial hypertension

European Respiratory Journal

Volumn 33, Issue 1, 2009, Pages 92-98

  Degano, B ^a,b   Yaici A ^a   Le Pavec, J ^a   Savale, L ^a   Jais X ^a   Camara, B ^b   Humbert, M ^a   Simonneau, G ^a   Sitbon, O ^a,c  

^a UNIVERSITÉ PARIS SACLAY   (France)

^b SERVICE DE PNEUMOLOGIE   (France)

^c HÔPITAL ANTOINE BÉCLÈRE   (France)

Author keywords

Bosentan; Endothelin; HIV; Hypertension; Pulmonary

Indexed keywords

ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; BOSENTAN; DIURETIC AGENT; ILOPROST; PROSTACYCLIN; SILDENAFIL;

ADULT; ANTIHYPERTENSIVE THERAPY; ARTICLE; CONTROLLED STUDY; DRUG EFFECT; DRUG EFFICACY; DRUG FATALITY; DRUG SAFETY; DRUG WITHDRAWAL; FEMALE; HEART HEMODYNAMICS; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFECTION CONTROL; LONG TERM CARE; LUNG VASCULAR RESISTANCE; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; OVERALL SURVIVAL; PRIORITY JOURNAL; PULMONARY HYPERTENSION; SURVIVAL TIME; WALKING DIFFICULTY;

ADULT; ANTIHYPERTENSIVE AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; COHORT STUDIES; DISEASE-FREE SURVIVAL; DRUG ADMINISTRATION SCHEDULE; EXERCISE TOLERANCE; FEMALE; HIV INFECTIONS; HUMANS; HYPERTENSION, PULMONARY; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES; SULFONAMIDES; TREATMENT OUTCOME;

EID: 58849130566     PISSN: 09031936     EISSN: 13993003     Source Type: Journal    
DOI: 10.1183/09031936.00094808     Document Type: Article

References (31)

1. Opravil M, Pechère M, Speich R, et al. HIV-associated primary pulmonary hypertension. A case control study. Swiss HIV Cohort Study. Am J Respir Crit Care Med 1997; 155: 990-995.
2. Sitbon O, Lascoux-Combe C, Delfraissy JF, et al. Prevalence of HIV-related pulmonary arterial hypertension in the current antiretroviral therapy era. Am J Respir Crit Care Med 2008; 177: 108-113.
3. Humbert M, Sitbon O, Chaouat A, et al. Pulmonary arterial hypertension in France: results from a national registry. Am J Respir Crit Care Med 2006; 173: 1023-1030.
4. Mehta NJ, Khan IA, Mehta RN, Sepkowitz DA. HIV-related pulmonary hypertension: analytic review of 131 cases. Chest 2000; 118: 1133-1141.
5. Nunes H, Humbert M, Sitbon O, et al. Prognostic factors for survival in human immunodeficiency virus-associated pulmonary arterial hypertension. Am J Respir Crit Care Med 2003; 167: 1433-1439.
6. Petitpretz P, Brenot F, Azarian R, et al. Pulmonary hypertension in patients with human immunodeficiency virus infection. Comparison with primary pulmonary hypertension. Circulation 1994; 89: 2722-2727.
7. Galiè N, Torbicki A, Barst R, et al. Guidelines on diagnosis and treatment of pulmonary arterial hypertension. The Task Force on Diagnosis and Treatment of Pulmonary Arterial Hypertension of the European Society of Cardiology. Eur Heart J 2004; 25: 2243-2278.
8. Pellicelli AM, Palmieri F, Cicalini S, Petrosillo N. Pathogenesis of HIV-related pulmonary hypertension. Ann N Y Acad Sci 2001; 946: 82-94.
9. Zuber JP, Calmy A, Evison JM, et al. Pulmonary arterial hypertension related to HIV infection: improved hemodynamics and survival associated with antiretroviral therapy. Clin Infect Dis 2004; 38: 1178-1185.
10. Sitbon O, Humbert M, Jaïs X, et al. Acute vasodilator responsiveness and long-term response to calcium-channel blockers in different forms of pulmonary arterial hypertension. Am J Respir Crit Care Med 2004; 169: A210.
11. Aguilar RV, Farber HW. Epoprostenol (prostacyclin) therapy in HIV-associated pulmonary hypertension. Am J Respir Crit Care Med 2000; 162: 1846-1850.
12. Ghofrani HA, Friese G, Discher T, et al. Inhaled iloprost is a potent acute pulmonary vasodilator in HIV-related severe pulmonary hypertension. Eur Respir J 2004; 23: 321-326.
13. Alp S, Schlottmann R, Bauer TT, Schmidt WE, Bastian A. Long-time survival with HIV-related pulmonary arterial hypertension: a case report. AIDS 2003; 17: 1714-1715.
14. Wong AR, Rasool AH, Abidin NZ, Noor AR, Quah BS. Sildenafil as treatment for human immunodeficiency virus-related pulmonary hypertension in a child. J Paediatr Child Health 2006; 42: 147-148.
15. Highleyman L. Protease inhibitors and sildenafil (Viagra) should not be combined. BETA 1999; 12: 3.
16. Price LC, Howard LS. Endothelin receptor antagonists for pulmonary arterial hypertension: rationale and place in therapy. Am J Cardiovasc Drugs 2008; 8: 171-185.
17. Sitbon O, Gressin V, Speich R, et al. Bosentan for the treatment of human immunodeficiency virus-associated pulmonary arterial hypertension. Am J Respir Crit Care Med 2004; 170: 1212-1217.
18. Sitbon O, Humbert M, Jaïs X, et al. Long-term calcium-channel blockers in idiopathic pulmonary arterial hypertension. Circulation 2005; 111: 3105-3111.
19. Humbert M, Sitbon O, Simonneau G. Treatment of pulmonary arterial hypertension. N Engl J Med 2004; 351: 1425-1436.
20. Sterne JA, Hernán MA, Ledergerber B, et al. Long-term effectiveness of potent antiretroviral therapy in preventing AIDS and death: a prospective cohort study. Lancet 2005; 366: 378-384.
21. Cohen H, Chahine C, Hui A, Mukherji R. Bosentan therapy for pulmonary arterial hypertension. Am J Health Syst Pharm 2004; 61: 1107-1119.
22. American Thoracic Society Committee on Proficiency Standards for Clinical Pulmonary Function Laboratories. ATS statement: guidelines for the six-minute walk test. Am J Respir Crit Care Med 2002; 166: 111-117.
23. Provencher S, Sitbon O, Humbert M, Cabrol S, Jaïs X, Simonneau G. Long-term outcome with first-line bosentan therapy in idiopathic pulmonary arterial hypertension. Eur Heart J 2006; 27: 589-595.
24. Montani D, Achouh L, Marcelin AG, et al. Reversibility of pulmonary arterial hypertension in HIV/HHV8-associated Castleman's disease. Eur Respir J 2005; 26: 969-972.
25. Humbert M, Monti G, Fartoukh M, et al. Platelet-derived growth factor expression in primary pulmonary hypertension: comparison of HIV seropositive and HIV seronegative patients. Eur Respir J 1998; 11: 554-559.
26. Ehrenreich H, Rieckmann P, Sinowatz F, et al. Potent stimulation of monocytic endothelin-1 production by HIV-1 glycoprotein 120. J Immunol 1993; 150: 4601-4609.
27. Barnett CF, Hsue PY, Machado RF. Pulmonary hypertension: an increasingly recognized complication of hereditary hemolytic anemias and HIV infection. JAMA 2008; 299: 324-331.
28. Delfraissy JF. République Française Ministère de la Santé et de la Protection Sociale. Prise en charge thérapeutique des personnes infectées par le VIH. Recommandations du groupe d'experts. Rapport 2004 sous la direction du Professeur JF Delfraissy, Ministère de la Santé et de la Protection Sociale. [Republic of France Ministry of Health and Social Protection. Therapeutic management of people infected with HIV. Recommendations of an expert group. 2004 report under the direction of Professor JF Delfraissy, Ministry of Health and Social Protection.] Paris, Médecines Sciences Flammarion, 2004. http://lesrapports. ladocumentationfrancaise.fr/BRP/044000467/0000.pdf
29. Humbert M, Segal ES, Kiely DG, Carlsen J, Schwierin B, Hoeper MM. Results of European post-marketing surveillance of bosentan in pulmonary hypertension. Eur Respir J 2007; 30: 338-344.
30. Rubin LJ, Badesch DB, Barst RJ, et al. Bosentan therapy for pulmonary arterial hypertension. N Engl J Med 2002; 346: 896-903.
31. Sitbon O, McLaughlin VV, Badesch DB, et al. Survival in patients with class III idiopathic pulmonary arterial hypertension treated with first line oral bosentan compared with an historical cohort of patients started on intravenous epoprostenol. Thorax 2005; 60: 1025-1030.